ALTERITY THERAPEUTICS LIMITED - Announcements

11.1%

0.8¢

Market Cap $108.7M

Healthcare Biotechnology

Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company.... Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

ATH	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/01/26	418.64KB	Share
ATH	ATH Shareholder Letter January 2026		21/01/26	227.6KB	Share
ATH	Notification regarding unquoted securities - ATH		15/01/26	16.85KB	Share
ATH	Notification regarding unquoted securities - ATH		15/01/26	16.83KB	Share
ATH	Corporate Presentation		13/01/26	2.16MB	Share
ATH	Change of Director's Interest Notice - D Stamler		07/01/26	915.21KB	Share
ATH	Notification of cessation of securities - ATH		07/01/26	13.77KB	Share
ATH	Initial Director's Interest Notice - Barbaczy		24/11/25	231.14KB	Share
ATH	Initial Director's Interest Notice - Stamler		24/11/25	3.37KB	Share
ATH	Final Director's Interest Notice - Meltzer		24/11/25	3.33KB	Share
ATH	Final Director's Interest Notice - Kempler		24/11/25	3.59KB	Share
ATH	Results of Meeting		21/11/25	243.74KB	Share
ATH	Presentation to Annual General Meeting		21/11/25	940.65KB	Share
ATH	Chairman's Address 2025 Annual General Meeting		21/11/25	142.2KB	Share
ATH	Alterity Board Changes	PRICE SENSITIVE	21/11/25	202.33KB	Share
ATH	Disclosure under Takeovers Panel GN 20		13/11/25	225.57KB	Share
ATH	Alterity to Present at the Bell Potter Healthcare Conference		12/11/25	170.45KB	Share
ATH	Alterity Presents Promising ATH434 Impact at AAS Symposium		10/11/25	213.49KB	Share
ATH	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/10/25	380.1KB	Share
ATH	Notice of Annual General Meeting/Proxy Form		21/10/25	616.69KB	Share
ATH	Change in substantial holding		14/10/25	250.62KB	Share
ATH	Alterity Presents Positive ATH434 Data at 2025 MDS Congress		09/10/25	226.1KB	Share
ATH	Alterity to Deliver Multiple Presentations at MDS Conference		02/10/25	209.9KB	Share
ATH	Alterity Reports New Commercial Assessment for ATH434 in MSA		29/09/25	2.31MB	Share
ATH	Date of AGM and Closing Date for Director Nominations		23/09/25	228.34KB	Share
ATH	Change of Director's Interest Notice x 4		17/09/25	50.4KB	Share
ATH	Notification of cessation of securities - ATH		17/09/25	13.79KB	Share
ATH	Change in substantial holding		17/09/25	575.44KB	Share
ATH	Alterity Presents Phase 2 Data at US Neurology Meeting		15/09/25	203.34KB	Share
ATH	Notice Under Section 708A		15/09/25	91.19KB	Share
ATH	Application for quotation of securities - ATH		15/09/25	17.25KB	Share
ATH	Proposed issue of securities - ATH		08/09/25	15.72KB	Share
ATH	Alterity Raises A$20.0 million in Strategic Placement	PRICE SENSITIVE	08/09/25	174.06KB	Share
ATH	Trading Halt	PRICE SENSITIVE	04/09/25	279.99KB	Share
ATH	Alterity Therapeutics Filed Form 20-F and XBRL Data with SEC		02/09/25	168.41KB	Share
ATH	Alterity Therapeutics to Present at the Biotech Showcase		01/09/25	227.19KB	Share
ATH	Corporate Governance Statement		29/08/25	267.95KB	Share
ATH	Appendix 4G		29/08/25	462.18KB	Share
ATH	Appendix 4E and 2025 Annual Report	PRICE SENSITIVE	29/08/25	1.68MB	Share
ATH	Application for quotation of securities - ATH		22/08/25	17.22KB	Share
ATH	Notification regarding unquoted securities - ATH		15/08/25	18.03KB	Share
ATH	Notification regarding unquoted securities - ATH		15/08/25	16.8KB	Share
ATH	Response to ASX Query Letters	PRICE SENSITIVE	04/08/25	701.88KB	Share
ATH	Updated Corporate Presentation		31/07/25	1.5MB	Share
ATH	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/07/25	369.11KB	Share
ATH	Positive ATH434 Results from Open-Label Phase 2 Trial in MSA	PRICE SENSITIVE	28/07/25	246.41KB	Share
ATH	Change in substantial holding		28/07/25	586.35KB	Share
ATH	Peer-Reviewed Publication on Novel MRI Endpoint from bioMUSE	PRICE SENSITIVE	24/07/25	226.65KB	Share
ATH	Application for quotation of securities - ATH		21/07/25	15.69KB	Share
ATH	Application for quotation of securities - ATH		17/07/25	16.22KB	Share
ATH	Response to ASX Price Query	PRICE SENSITIVE	14/07/25	308.69KB	Share
ATH	Change in substantial holding		07/07/25	405.91KB	Share
ATH	Notification regarding unquoted securities - ATH		03/07/25	16.77KB	Share
ATH	Notification of cessation of securities - ATH		30/06/25	13.52KB	Share
ATH	Alterity CEO to Provide Corporate Update on ATH434		23/06/25	172.46KB	Share
ATH	Change in substantial holding		23/05/25	459.93KB	Share
ATH	Alterity Prominently Featured at International MSA Congress		12/05/25	248.27KB	Share
ATH	Change in substantial holding		12/05/25	443.5KB	Share
ATH	Alterity Phase 2 Data to be Featured at MSA Congress		07/05/25	208.38KB	Share
ATH	Alterity Granted U.S. FDA Fast Track Designation for ATH434	PRICE SENSITIVE	05/05/25	233.86KB	Share
ATH	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/04/25	356.37KB	Share
ATH	Change of Director's Interest Notice x 3		29/04/25	20.43KB	Share
ATH	Alterity Phase 2 Presentation at MSA Symposium 2025		28/04/25	1.12MB	Share
ATH	New Options - Top 20 Holders and Range of Units		22/04/25	83.18KB	Share
ATH	Application for quotation of securities - ATH		22/04/25	17.96KB	Share
ATH	Updated Corporate Presentation		22/04/25	1.25MB	Share
ATH	Options Prospectus	PRICE SENSITIVE	17/04/25	418.67KB	Share
ATH	Alterity Phase 2 Presentation at AAN 2025	PRICE SENSITIVE	10/04/25	910.47KB	Share
ATH	Alterity Presents Encouraging New Phase 2 Data in MSA	PRICE SENSITIVE	10/04/25	214.77KB	Share
ATH	Change of Director's Interest Notice x 3		09/04/25	19.35KB	Share
ATH	Becoming a substantial holder		08/04/25	93.51KB	Share
ATH	Change in substantial holding		08/04/25	387.78KB	Share
ATH	Completion of Placement		07/04/25	193.24KB	Share
ATH	Notice Under Section 708A		07/04/25	91.2KB	Share
ATH	Application for quotation of securities - ATH		07/04/25	15.87KB	Share
ATH	Alterity to Deliver Oral Presentation of ATH434 Trial at AAN		03/04/25	201.52KB	Share
ATH	Results of Meeting		31/03/25	25.59KB	Share
ATH	Alterity Completes Last Patient Visit in Open-Label Trial	PRICE SENSITIVE	27/03/25	200.8KB	Share
ATH	Ceasing to be a substantial holder		24/03/25	754.11KB	Share
ATH	Application for quotation of securities - ATH		14/03/25	15.63KB	Share
ATH	Becoming a substantial holder		13/03/25	944.45KB	Share
ATH	Notice of Extraordinary General Meeting/Proxy Form		28/02/25	469.1KB	Share
ATH	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/25	709.07KB	Share
ATH	Proposed issue of securities - ATH		24/02/25	16.95KB	Share
ATH	Change in substantial holding		19/02/25	476.17KB	Share
ATH	Notice Under Section 708A		17/02/25	105.51KB	Share
ATH	Application for quotation of securities - ATH		17/02/25	15.97KB	Share
ATH	Proposed issue of securities - ATH		10/02/25	19.4KB	Share
ATH	Alterity raises A$40m to Advance ATH434 Development in MSA	PRICE SENSITIVE	10/02/25	182.76KB	Share
ATH	Ceasing to be a substantial holder		07/02/25	326.38KB	Share
ATH	Trading Halt	PRICE SENSITIVE	06/02/25	272.28KB	Share
ATH	Becoming a substantial holder		06/02/25	403.04KB	Share
ATH	Disclosure under Takeovers Panel GN 20		05/02/25	308.67KB	Share
ATH	Change in substantial holding		05/02/25	514.11KB	Share
ATH	Notice Under Section 708A		04/02/25	103.02KB	Share
ATH	Application for quotation of securities - ATH		04/02/25	15.67KB	Share
ATH	Proposed issue of securities - ATH		03/02/25	15.15KB	Share
ATH	Alterity Raises Funds for ATH434 BD and Clinical Activities	PRICE SENSITIVE	03/02/25	196.99KB	Share
ATH	Application for quotation of securities - ATH		30/01/25	15.75KB	Share
ATH	ATH434-201 Phase 2 Topline Results Presentation		30/01/25	1.91MB	Share

ATH Quarterly Activities/Appendix 4C Cash Flow Report
30/01/26	PRICE SENSITIVE	418.64KB	Share
ATH ATH Shareholder Letter January 2026
21/01/26		227.6KB	Share
ATH Notification regarding unquoted securities - ATH
15/01/26		16.85KB	Share
ATH Notification regarding unquoted securities - ATH
15/01/26		16.83KB	Share
ATH Corporate Presentation
13/01/26		2.16MB	Share
ATH Change of Director's Interest Notice - D Stamler
07/01/26		915.21KB	Share
ATH Notification of cessation of securities - ATH
07/01/26		13.77KB	Share
ATH Initial Director's Interest Notice - Barbaczy
24/11/25		231.14KB	Share
ATH Initial Director's Interest Notice - Stamler
24/11/25		3.37KB	Share
ATH Final Director's Interest Notice - Meltzer
24/11/25		3.33KB	Share
ATH Final Director's Interest Notice - Kempler
24/11/25		3.59KB	Share
ATH Results of Meeting
21/11/25		243.74KB	Share
ATH Presentation to Annual General Meeting
21/11/25		940.65KB	Share
ATH Chairman's Address 2025 Annual General Meeting
21/11/25		142.2KB	Share
ATH Alterity Board Changes
21/11/25	PRICE SENSITIVE	202.33KB	Share
ATH Disclosure under Takeovers Panel GN 20
13/11/25		225.57KB	Share
ATH Alterity to Present at the Bell Potter Healthcare Conference
12/11/25		170.45KB	Share
ATH Alterity Presents Promising ATH434 Impact at AAS Symposium
10/11/25		213.49KB	Share
ATH Quarterly Activities/Appendix 4C Cash Flow Report
31/10/25	PRICE SENSITIVE	380.1KB	Share
ATH Notice of Annual General Meeting/Proxy Form
21/10/25		616.69KB	Share
ATH Change in substantial holding
14/10/25		250.62KB	Share
ATH Alterity Presents Positive ATH434 Data at 2025 MDS Congress
09/10/25		226.1KB	Share
ATH Alterity to Deliver Multiple Presentations at MDS Conference
02/10/25		209.9KB	Share
ATH Alterity Reports New Commercial Assessment for ATH434 in MSA
29/09/25		2.31MB	Share
ATH Date of AGM and Closing Date for Director Nominations
23/09/25		228.34KB	Share
ATH Change of Director's Interest Notice x 4
17/09/25		50.4KB	Share
ATH Notification of cessation of securities - ATH
17/09/25		13.79KB	Share
ATH Change in substantial holding
17/09/25		575.44KB	Share
ATH Alterity Presents Phase 2 Data at US Neurology Meeting
15/09/25		203.34KB	Share
ATH Notice Under Section 708A
15/09/25		91.19KB	Share
ATH Application for quotation of securities - ATH
15/09/25		17.25KB	Share
ATH Proposed issue of securities - ATH
08/09/25		15.72KB	Share
ATH Alterity Raises A$20.0 million in Strategic Placement
08/09/25	PRICE SENSITIVE	174.06KB	Share
ATH Trading Halt
04/09/25	PRICE SENSITIVE	279.99KB	Share
ATH Alterity Therapeutics Filed Form 20-F and XBRL Data with SEC
02/09/25		168.41KB	Share
ATH Alterity Therapeutics to Present at the Biotech Showcase
01/09/25		227.19KB	Share
ATH Corporate Governance Statement
29/08/25		267.95KB	Share
ATH Appendix 4G
29/08/25		462.18KB	Share
ATH Appendix 4E and 2025 Annual Report
29/08/25	PRICE SENSITIVE	1.68MB	Share
ATH Application for quotation of securities - ATH
22/08/25		17.22KB	Share
ATH Notification regarding unquoted securities - ATH
15/08/25		18.03KB	Share
ATH Notification regarding unquoted securities - ATH
15/08/25		16.8KB	Share
ATH Response to ASX Query Letters
04/08/25	PRICE SENSITIVE	701.88KB	Share
ATH Updated Corporate Presentation
31/07/25		1.5MB	Share
ATH Quarterly Activities/Appendix 4C Cash Flow Report
30/07/25	PRICE SENSITIVE	369.11KB	Share
ATH Positive ATH434 Results from Open-Label Phase 2 Trial in MSA
28/07/25	PRICE SENSITIVE	246.41KB	Share
ATH Change in substantial holding
28/07/25		586.35KB	Share
ATH Peer-Reviewed Publication on Novel MRI Endpoint from bioMUSE
24/07/25	PRICE SENSITIVE	226.65KB	Share
ATH Application for quotation of securities - ATH
21/07/25		15.69KB	Share
ATH Application for quotation of securities - ATH
17/07/25		16.22KB	Share
ATH Response to ASX Price Query
14/07/25	PRICE SENSITIVE	308.69KB	Share
ATH Change in substantial holding
07/07/25		405.91KB	Share
ATH Notification regarding unquoted securities - ATH
03/07/25		16.77KB	Share
ATH Notification of cessation of securities - ATH
30/06/25		13.52KB	Share
ATH Alterity CEO to Provide Corporate Update on ATH434
23/06/25		172.46KB	Share
ATH Change in substantial holding
23/05/25		459.93KB	Share
ATH Alterity Prominently Featured at International MSA Congress
12/05/25		248.27KB	Share
ATH Change in substantial holding
12/05/25		443.5KB	Share
ATH Alterity Phase 2 Data to be Featured at MSA Congress
07/05/25		208.38KB	Share
ATH Alterity Granted U.S. FDA Fast Track Designation for ATH434
05/05/25	PRICE SENSITIVE	233.86KB	Share
ATH Quarterly Activities/Appendix 4C Cash Flow Report
30/04/25	PRICE SENSITIVE	356.37KB	Share
ATH Change of Director's Interest Notice x 3
29/04/25		20.43KB	Share
ATH Alterity Phase 2 Presentation at MSA Symposium 2025
28/04/25		1.12MB	Share
ATH New Options - Top 20 Holders and Range of Units
22/04/25		83.18KB	Share
ATH Application for quotation of securities - ATH
22/04/25		17.96KB	Share
ATH Updated Corporate Presentation
22/04/25		1.25MB	Share
ATH Options Prospectus
17/04/25	PRICE SENSITIVE	418.67KB	Share
ATH Alterity Phase 2 Presentation at AAN 2025
10/04/25	PRICE SENSITIVE	910.47KB	Share
ATH Alterity Presents Encouraging New Phase 2 Data in MSA
10/04/25	PRICE SENSITIVE	214.77KB	Share
ATH Change of Director's Interest Notice x 3
09/04/25		19.35KB	Share
ATH Becoming a substantial holder
08/04/25		93.51KB	Share
ATH Change in substantial holding
08/04/25		387.78KB	Share
ATH Completion of Placement
07/04/25		193.24KB	Share
ATH Notice Under Section 708A
07/04/25		91.2KB	Share
ATH Application for quotation of securities - ATH
07/04/25		15.87KB	Share
ATH Alterity to Deliver Oral Presentation of ATH434 Trial at AAN
03/04/25		201.52KB	Share
ATH Results of Meeting
31/03/25		25.59KB	Share
ATH Alterity Completes Last Patient Visit in Open-Label Trial
27/03/25	PRICE SENSITIVE	200.8KB	Share
ATH Ceasing to be a substantial holder
24/03/25		754.11KB	Share
ATH Application for quotation of securities - ATH
14/03/25		15.63KB	Share
ATH Becoming a substantial holder
13/03/25		944.45KB	Share
ATH Notice of Extraordinary General Meeting/Proxy Form
28/02/25		469.1KB	Share
ATH Half Yearly Report and Accounts
28/02/25	PRICE SENSITIVE	709.07KB	Share
ATH Proposed issue of securities - ATH
24/02/25		16.95KB	Share
ATH Change in substantial holding
19/02/25		476.17KB	Share
ATH Notice Under Section 708A
17/02/25		105.51KB	Share
ATH Application for quotation of securities - ATH
17/02/25		15.97KB	Share
ATH Proposed issue of securities - ATH
10/02/25		19.4KB	Share
ATH Alterity raises A$40m to Advance ATH434 Development in MSA
10/02/25	PRICE SENSITIVE	182.76KB	Share
ATH Ceasing to be a substantial holder
07/02/25		326.38KB	Share
ATH Trading Halt
06/02/25	PRICE SENSITIVE	272.28KB	Share
ATH Becoming a substantial holder
06/02/25		403.04KB	Share
ATH Disclosure under Takeovers Panel GN 20
05/02/25		308.67KB	Share
ATH Change in substantial holding
05/02/25		514.11KB	Share
ATH Notice Under Section 708A
04/02/25		103.02KB	Share
ATH Application for quotation of securities - ATH
04/02/25		15.67KB	Share
ATH Proposed issue of securities - ATH
03/02/25		15.15KB	Share
ATH Alterity Raises Funds for ATH434 BD and Clinical Activities
03/02/25	PRICE SENSITIVE	196.99KB	Share
ATH Application for quotation of securities - ATH
30/01/25		15.75KB	Share
ATH ATH434-201 Phase 2 Topline Results Presentation
30/01/25		1.91MB	Share

REFRESH

1 2 3 4 5 6

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 0.8¢		Change -0.001(11.1%)		Mkt cap ! $108.7M

Open	High	Low	Volume
0.9¢	0.9¢	0.8¢	368.0K

Buyers (Bids)

Vol.	Price($)
1241808	0.8¢

Sellers (Offers)

Price($)	Vol.
0.9¢	12015089

Last trade - 13.05pm 12/02/2026 (20 minute delay)

ATH (ASX) Chart

ALTERITY THERAPEUTICS LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available